DERM
NASDAQJourney Medical Corporation
Price$5.15+0.08 (+1.48%)
02:15 PM07:45 PM
News · 26 weeks150%
2025-10-262026-04-19
Mix690d
- Earnings2(33%)
- SEC Filings2(33%)
- Other2(33%)
Latest news
25 items- SECJourney Medical Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Secures Contract with Third Major GPO for Emrosi™SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical" or "the Company", "we", or "our"), a commercial-stage pharmaceutical company primarily focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that approximately 85% of all commercial lives in the United States now have access to Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) after contracting with the third major group purchasing organization (GPO). Emrosi™ is for the treatment of inflammatory lesions o
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Journey Medical CorporationSCHEDULE 13G/A - Journey Medical Corp (0001867066) (Subject)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate HighlightsTotal revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately 53,000 total prescriptions were filled for Emrosi™ during FY2025 Payer access for Emrosi™ available to over 100 million U.S. commercial lives Company to hold conference call today at 4:30 p.m. ET SCOTTSDALE, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved prescription pharmaceutical products for t
- PRJourney Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its year end 2025 financial results after the U.S. financial markets close on Wednesday, March 25, 2026. Journey Medical management will conduct a conference call and audio webcast on Wednesday, March 25, 2026 at 4:30 p.m. ET. To listen to the conference call, interested parties within the U.S. shoul
- SECSEC Form 424B3 filed by Journey Medical Corporation424B3 - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form 424B3 filed by Journey Medical Corporation424B3 - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form EFFECT filed by Journey Medical CorporationEFFECT - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form S-3 filed by Journey Medical CorporationS-3 - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in DermatologyClinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical"), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administrat
- SECSEC Form 10-Q filed by Journey Medical Corporation10-Q - Journey Medical Corp (0001867066) (Filer)
- SECJourney Medical Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation Reports Third Quarter 2025 Financial Results and Recent Corporate HighlightsThird quarter 2025 net revenues were $17.6 million Emrosi™ total prescriptions increased 146% over the second quarter of 2025 Emrosi net revenues were $4.9 million Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ:DERM) ("Journey Medical," "the Company," "we" or "our"), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the third quar
- PRJourney Medical Corporation to Announce Third Quarter 2025 Financial Results on November 12, 2025SCOTTSDALE, Ariz., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or the "Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its third quarter 2025 financial results after the U.S. financial markets close on Wednesday, November 12, 2025. Journey Medical management will conduct a conference call and audio webcast on Wednesday, November 12, 2025 at 4:30 p.m. ET. To listen to the conference call, interested parties within the
- PRJourney Medical Corporation Reports Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial Efficacy Data Analysis Presented at the 2025 Fall Clinical Dermatology ConferenceFDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults DFD-29 demonstrated superior efficacy in IGA success rates and inflammatory lesion counts versus both placebo and doxycycline (P<0.001 for all comparisons) Poster Presented on Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, in Patients with Rosacea: A Pooled Analysis of Two Phase 3 Trials SCOTTSDALE, Ariz., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceut
- PRJourney Medical Corporation to Participate in October 2025 Investor ConferencesSCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will participate in two October 2025 investor conferences. Details of the events are as follows: 4th Annual ROTH Healthcare Opportunities ConferenceDate: Thursday, October 9, 2025Location: New York CityFormat: 1x1 Meetings The ThinkEquity Conference Date: Thursday, October 3
- SECJourney Medical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation8-K - Journey Medical Corp (0001867066) (Filer)
- PRJourney Medical Corporation to Participate in September 2025 Investor ConferencesSCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation ("Journey Medical" or "the Company") (NASDAQ:DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration ("FDA")-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences. Details of the events are as follows: H.C. Wainwright 27th Annual Global Investment Conference Date and Time: Monday, September 8, 2025, at 1:30 p.m. ETLocation: New York CityFormat: Fireside
- SECJourney Medical Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - Journey Medical Corp (0001867066) (Filer)
- SECSEC Form 424B3 filed by Journey Medical Corporation424B3 - Journey Medical Corp (0001867066) (Filer)
- INSIDERPresident & CEO Maraoui Claude exercised 1,250,000 shares at a strike of $0.07 and covered exercise/tax liability with 10,877 shares, increasing direct ownership by 108% to 2,386,713 units (SEC Form 4)4 - Journey Medical Corp (0001867066) (Issuer)
- ANALYSTH.C. Wainwright initiated coverage on Journey Medical with a new price targetH.C. Wainwright initiated coverage of Journey Medical with a rating of Buy and set a new price target of $13.00
- PRPresenting on Emerging Growth Conference 85 Day 2 on August 21; Register to live streamMIAMI, Aug. 20, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter Day 1 – Presenting Today, August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered
- PRPresenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live streamMIAMI, Aug. 19, 2025 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 85th Emerging Growth Conference on August 20 & 21, 2025. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting companies to: Questions@EmergingGrowth.com For updates, follow us on Twitter. Day 1August 20, 2025 8:45Virtual Lobby opens.Register for the Conference. If you already registered, go back to the reg